Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
Public ClinicalTrials.gov record NCT00663026. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Safety, Tolerability, Reactogenicity, And Pharmacokinetic Study Of Bapineuzumab (AAB 001) Administered Subcutaneously In Subjects With Mild To Moderate AD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will evaluate the safety and effectiveness of bapineuzumab for the treatment of mild to moderate Alzheimer disease. Subjects will be in the study for six months and will receive subcutaneous injections once per week.
Study identification
- NCT ID
- NCT00663026
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 79 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 89 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2008 (Type not available)
- Primary completion
- Oct 2010 (Actual)
- Completion
- Oct 2010 (Actual)
- Last update posted
- Nov 15, 2013
2008 – 2010
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Phoenix | Arizona | 85006 | — |
| Pfizer Investigational Site | Sun City | Arizona | 85351 | — |
| Pfizer Investigational Site | Encino | California | 91316 | — |
| Pfizer Investigational Site | Los Alamitos | California | 90720 | — |
| Pfizer Investigational Site | Newport Beach | California | 92660 | — |
| Pfizer Investigational Site | Delray Beach | Florida | 33445 | — |
| Pfizer Investigational Site | Hallandale | Florida | 33009 | — |
| Pfizer Investigational Site | West Palm Beach | Florida | 33407 | — |
| Pfizer Investigational Site | Decatur | Georgia | 30033 | — |
| Pfizer Investigational Site | Lawrenceville | Georgia | 30045 | — |
| Pfizer Investigational Site | Wichita | Kansas | 67211 | — |
| Pfizer Investigational Site | Rochester | New York | 14620 | — |
| Pfizer Investigational Site | East Providence | Rhode Island | 02914 | — |
| Pfizer Investigational Site | Providence | Rhode Island | 02906 | — |
| Pfizer Investigational Site | Dallas | Texas | 75214 | — |
| Pfizer Investigational Site | Bennington | Vermont | 05201 | — |
| Pfizer Investigational Site | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00663026, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 15, 2013 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00663026 live on ClinicalTrials.gov.